S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
S&P 500   3,811.15 (-0.48%)
DOW   30,932.37 (-1.50%)
QQQ   314.14 (+0.42%)
AAPL   121.26 (+0.22%)
MSFT   232.38 (+1.48%)
FB   257.62 (+1.15%)
GOOGL   2,021.91 (+0.30%)
AMZN   3,092.93 (+1.17%)
TSLA   675.50 (-0.99%)
NVDA   548.58 (+3.06%)
BABA   237.76 (-1.01%)
CGC   32.75 (-1.39%)
GE   12.54 (-1.72%)
MU   91.53 (+3.87%)
NIO   45.78 (-2.20%)
AMD   84.51 (+2.54%)
T   27.89 (-2.58%)
F   11.70 (-0.51%)
ACB   10.52 (-2.77%)
DIS   189.04 (-1.02%)
BA   212.01 (-2.05%)
NFLX   538.85 (-1.44%)
BAC   34.71 (-3.40%)
Log in
NASDAQ:ORGS

Orgenesis Stock Forecast, Price & News

$6.69
-0.20 (-2.90 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.65
Now: $6.69▼
$7.02
50-Day Range
$4.93
MA: $6.31▼
$7.12
52-Week Range
$2.76
Now: $6.69▼
$8.20
Volume170,964 shs
Average Volume188,486 shs
Market Capitalization$161.60 million
P/E Ratio1.44
Dividend YieldN/A
Beta1.16
Orgenesis Inc. offers biotechnology solutions focusing on cell and gene therapies (CGTs). The company's Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on identification of new therapies and leverages its POCare platform to provide a pathway for these therapies to treat patients. Additionally, the company's Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies. Orgenesis Inc. was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. The company was founded in 2008 and is based in Germantown, Maryland.

Headlines

Orgenesis to Present Today at the Winter Wonderland Conference-Best Ideas from the Buy-Side
February 16, 2021 |  finance.yahoo.com
Is Orgenesis (NASDAQ:ORGS) Using Debt In A Risky Way?
January 25, 2021 |  finance.yahoo.com
Orgenesis Third Quarter 2020 Revenue Increases 40% Reflecting Continued Progress of POCare Platform
November 5, 2020 |  finance.yahoo.com
Orgenesis Announces Virtual 2020 Annual Meeting of Stockholders
November 3, 2020 |  finance.yahoo.com
Did Orgenesis' (NASDAQ:ORGS) Share Price Deserve to Gain 44%?
October 26, 2020 |  finance.yahoo.com
Orgenesis Completes Acquisition of Koligo Therapeutics and Announces Additional Acquisition of Icellator® Technology from Tissue Genesis in Related Transaction
October 19, 2020 |  finance.yahoo.com
Orgenesis to acquire Louisville-based Koligo Therapeutics
September 29, 2020 |  bizjournals.com
Orgenesis to acquire Koligo Therapeutics
September 29, 2020 |  seekingalpha.com
Orgenesis to boost KYSLECEL commercialization through Koligo Therapeutics acquisition
September 29, 2020 |  seekingalpha.com
AIM ImmunoTech CEO to Participate in Virtual Panel: 'New Approaches to COVID-19: Hidden Breakthroughs,' on Thursday, September 10th
September 9, 2020 |  finance.yahoo.com
Orgenesis CEO to Participate in Webinar Panel on “New Approaches to COVID-19” on Thursday, September 10th
September 9, 2020 |  finance.yahoo.com
Orgenesis Selects Therapeutics, Inc. as CRO to Support Development and Planned Phase 2 Clinical Study of Ranpirnase for the Treatment of External Genital Warts
August 20, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORGS
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.orgenesis.com
Phone480 659 6404
Employees309
Year FoundedN/A

Debt

Debt-to-Equity Ratio0.12
Current Ratio7.69
Quick Ratio7.68

Price-To-Earnings

Trailing P/E Ratio1.44
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$33.26 million
Price / Sales4.86
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.38 per share
Price / Book17.61

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-28,220,000.00
Net Margins600.61%
Return on Equity6.25%
Return on Assets3.77%

Miscellaneous

Outstanding Shares24,156,000
Market Cap$161.60 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.25 out of 5 stars

Medical Sector

1753rd out of 1,956 stocks

Pharmaceutical Preparations Industry

718th out of 769 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
$6.69
-0.20 (-2.90 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ORGS News and Ratings via Email

Sign-up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Orgenesis (NASDAQ:ORGS) Frequently Asked Questions

What stocks does MarketBeat like better than Orgenesis?

Wall Street analysts have given Orgenesis a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Orgenesis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Orgenesis' next earnings date?

Orgenesis is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Orgenesis.

How were Orgenesis' earnings last quarter?

Orgenesis Inc. (NASDAQ:ORGS) issued its earnings results on Monday, May, 11th. The company reported ($0.39) EPS for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.19. The company earned $1.88 million during the quarter. Orgenesis had a net margin of 600.61% and a trailing twelve-month return on equity of 6.25%.
View Orgenesis' earnings history.

How has Orgenesis' stock price been impacted by Coronavirus?

Orgenesis' stock was trading at $3.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ORGS shares have increased by 73.3% and is now trading at $6.69.
View which stocks have been most impacted by COVID-19.

Who are Orgenesis' key executives?

Orgenesis' management team includes the following people:
  • Ms. Vered Caplan, Chairperson of the Board, CEO & Pres (Age 52, Pay $527.02k)
  • Mr. Neil T. Reithinger, CFO, Sec. & Treasurer (Age 51, Pay $213.65k)
  • Prof. Sarah Ferber, Founder & Chief Scientific Officer (Age 67)
  • Mr. Evan Fishman, Chief Financial Officer
  • Mr. Joseph Green, Chief Operating Officer

Who are some of Orgenesis' key competitors?

Some companies that are related to Orgenesis include Atreca (BCEL), Basilea Pharmaceutica (BPMUF), Chimerix (CMRX), BELLUS Health (BLUSF), KalVista Pharmaceuticals (KALV), Foghorn Therapeutics (FHTX), Ardelyx (ARDX), Eagle Pharmaceuticals (EGRX), Evelo Biosciences (EVLO), Inventiva (IVA), Summit Therapeutics (SMMT), XBiotech (XBIT), Geron (GERN), IDEAYA Biosciences (IDYA) and Applied Therapeutics (APLT).
View all of ORGS's competitors.

What is Orgenesis' stock symbol?

Orgenesis trades on the NASDAQ under the ticker symbol "ORGS."

Who are Orgenesis' major shareholders?

Orgenesis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.04%), Phoenix Holdings Ltd. (3.07%), Renaissance Technologies LLC (1.16%), Nuveen Asset Management LLC (0.39%), JPMorgan Chase & Co. (0.24%) and Wells Fargo & Company MN (0.20%).
View institutional ownership trends for Orgenesis.

Which major investors are selling Orgenesis stock?

ORGS stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Phoenix Holdings Ltd., and Bank of New York Mellon Corp.
View insider buying and selling activity for Orgenesis or view top insider-selling stocks.

Which major investors are buying Orgenesis stock?

ORGS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, JPMorgan Chase & Co., Wells Fargo & Company MN, Rhumbline Advisers, Nuveen Asset Management LLC, and Barclays PLC.
View insider buying and selling activity for Orgenesis or or view top insider-buying stocks.

How do I buy shares of Orgenesis?

Shares of ORGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Orgenesis' stock price today?

One share of ORGS stock can currently be purchased for approximately $6.69.

How much money does Orgenesis make?

Orgenesis has a market capitalization of $161.60 million and generates $33.26 million in revenue each year.

How many employees does Orgenesis have?

Orgenesis employs 309 workers across the globe.

What is Orgenesis' official website?

The official website for Orgenesis is www.orgenesis.com.

Where are Orgenesis' headquarters?

Orgenesis is headquartered at 20271 Goldenrod Lane, Germantown MD, 20876.

How can I contact Orgenesis?

Orgenesis' mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 480 659 6404 or via email at [email protected]


This page was last updated on 2/26/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.